Related Experiment Videos
[Postoperative histologic evaluation of hepatocarcinoma treated using chemo-embolization]
M Castrucci1, S Sironi, A Vanzulli
1Radiologia Diagnostica, Istituto Scientifico Ospedale S. Raffaele, Universitá, Milano
La Radiologia Medica
|July 1, 1990
Summary
Transcatheter arterial chemoembolization (TAE) effectively treats hepatocellular carcinoma (HCC) by preventing tumor growth and thickening the capsule. This approach enhances surgical safety and reduces recurrence risk in operable HCC patients.
Area of Science:
- Hepatobiliary Surgery
- Interventional Radiology
- Oncology
Background:
- Transcatheter arterial chemoembolization (TAE) is a recognized palliative treatment for inoperable hepatocellular carcinoma (HCC).
- TAE is increasingly explored in operable HCC cases to mitigate postoperative recurrence.
- Histopathologic evaluation of chemoembolized, resected HCCs is crucial for understanding treatment efficacy.
Purpose of the Study:
- To assess the histopathologic alterations in surgically resected hepatocellular carcinoma (HCC) following transcatheter arterial chemoembolization (TAE).
- To evaluate the impact of TAE on tumor viability, capsule formation, and potential for recurrence in operable HCC.
Main Methods:
- Five patients with operable HCC underwent TAE using Lipiodol-Adriamycin and Spongostan embolization.
- Computed Tomography (CT) was used for post-TAE tumor size assessment.
- Surgical resection (partial hepatectomy) followed TAE, with subsequent histopathologic examination of resected specimens.
Main Results:
- CT scans showed no increase in tumor size post-TAE in all patients.
- Histopathology revealed a thickened fibrous capsule around all treated HCCs.
- Complete tumor necrosis was observed in 4 out of 5 cases; one case showed viable tumor and emboli.
Conclusions:
- TAE is beneficial in operable HCC by inhibiting tumor progression and enhancing capsule formation.
- These effects potentially improve surgical safety and decrease the likelihood of HCC recurrence.
- TAE demonstrates promise as a neoadjuvant therapy for resectable HCC.